SPNE - SeaSpine guides Q4 and FY2020 revenue below consensus

SeaSpine Holdings Corporation (SPNE) expects Q4 revenue in the range of $46.2M-$46.6M (+6 to +7% Y/Y) vs. consensus of $47.27M. U.S. Spinal Implants revenue is expected to reflect growth within the 7% to 8% range and U.S. Orthobiologics revenue is expected to reflect growth within the 6% to 7% range.International revenue is expected to decrease 3% to ~$4.3M for the quarter. FY2020 revenue is expected to be in the range of $154.1M to $154.5M (-3% Y/Y) vs. consensus of $155.18M. “We were pleased by our ability to generate record quarterly revenue and meaningful revenue growth in the fourth quarter, despite the larger impact of the pandemic on surgery volumes compared to the third quarter, and particularly as compared to the 21% growth we reported for the U.S. Spinal Implants portfolio in the fourth quarter of 2019,” said Keith Valentine, President and Chief Executive Officer. Cash, cash equivalents and short-term investments

For further details see:

SeaSpine guides Q4 and FY2020 revenue below consensus